Abstract
Background Few cases or peri-implant peripheral giant cell lesions (PGCL) have been reported in the literature. The aim of this study was to report 13 new cases of peri-implant PGCL and compare the expression of smooth muscle actin, Bcl-2 protein, GLUT-1, CD68, osteoprotegerin, receptor activator of nuclear factor kappa-B, Ki-67 and CD34 in these cases with PGCL and central giant cell lesions (CGCL). Material and Methods Clinical data were retrieved from the laboratory records and histological analysis was performed using HE-stained slides. Immunohistochemical reactions for the above mentioned antibodies were performed and digitally scored. Results Peri-implant PGCL mostly affected the posterior mandible of adult females. CD68 and Bcl-2 expressions were higher in conventional PGCL and CGCL than in peri-implant PGCL (p=0.033 for CD68 and p<.0001 for Bcl-2). Microvessel density was higher in conventional peripheral than in central and peri-implant PGCL (p=0.002). Proliferative index of the mononuclear cells showed no statistically significant differences comparing the three groups but it was higher in peri-implant PGCL. Conclusions The current study demonstrated that peri-implant PGCL is more common in the posterior mandible of adult females. There were some differences in microvessel density, proliferative activity and expression of CD68 and Bcl-2 among conventional PGCL, peri-implant and CGCL. Further studies are encouraged to better understand these early findings. Key words:Giant cell lesion, giant cell granuloma, peripheral, dental implants, immunohistochemistry.
Highlights
Peripheral giant cell lesions (PGCL) are relatively common proliferative growths that affect mainly the lower posterior gingiva and edentulous areas of the alveolar mucosa [1]
It is interesting to notice that most cases were clinically interpreted as pyogenic granulomas, but clinicians should be aware that peripheral giant cell lesions (PGCL) can be associated with dental implants
The present results showed that both the mean number of multinucleated giant cells per high-power field and the proportion of ovoid/spindled mononuclear mesenchymal cells to multinucleated giant cells were similar for central giant cell lesions (CGCL), conventional PGCL and peri-implant PGCL
Summary
Peripheral giant cell lesions (PGCL) are relatively common proliferative growths that affect mainly the lower posterior gingiva and edentulous areas of the alveolar mucosa [1]. Conventional PGCL, peri-implant PGCL and CGCL are histologically similar, but their pathogenesis remains poorly understood. There is no previously published comparative study including peri-implant PGCL and it is not known whether the expression of metabolism markers and proteins involved in osteoclast activation pathways and apoptosis can be different when comparing these 3 groups. Few cases or peri-implant peripheral giant cell lesions (PGCL) have been reported in the literature. The aim of this study was to report 13 new cases of peri-implant PGCL and compare the expression of smooth muscle actin, Bcl-2 protein, GLUT-1, CD68, osteoprotegerin, receptor activator of nuclear factor kappa-B, Ki-67 and CD34 in these cases with PGCL and central giant cell lesions (CGCL). There were some differences in microvessel density, proliferative activity and expression of CD68 and Bcl-2 among conventional PGCL, peri-implant and CGCL. Further studies are encouraged to better understand these early findings
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
